Personalised Pharmacotherapy with Sertraline in Patients with Anxiety—Depressive Disorder Based on Omics Biomarkers
Молекулярная биология / Molecular Biology · 2025 · 59 (6) · 928
DOI: 10.7868/s3034555325060041 ↗Kurz gefasst
Fachartikel in der Zeitschrift Молекулярная биология / Molecular Biology, 2025. Verfasst von A E Gareeva und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, 450054 Russia. Hauptthemen laut MEDLINE: Sertraline, Precision Medicine, Cytochrome P-450 CYP2D6, Anxiety Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Sertraline, a selective serotonin reuptake inhibitor, is widely used as a first-line drug for anxiety and depressive disorders. Clinical efficacy and adverse reactions observed with antidepressants are closely related to the concentration of the drug in the patient’s blood, but the vast majority of antidepressants demonstrate significant pharmacokinetic variability, leading to pronounced interindividual differences in the steady-state concentration of the drug in the blood and its efficacy even with the same dosing regimen. In this regard, it becomes obvious that genetic markers alone are not enough to obtain the most complete profile of the efficacy and safety of a drug; a combination of genotyping methods with omics biomarkers is necessary. As a result of examination of patients diagnosed with mixed anxiety-depressive disorder (F41.2), residents of the Republic of Bashkortostan, it was found that polymorphic variants rs16947 (CYP2D6*2), rs389209 (CYP2D6*4), rs1065852 (CYP2D6*10) of the CYP2D6 gene do not have a significant effect on the activity of CYP2D6. Genetically determined variations in the activity of the CYP2D6 isoenzyme lead to differences in the metabolism of sertraline and its active metabolite N-desmethylsertraline in different patients, which causes variability in their concentrations in blood plasma. A statistically significant increase in the plasma concentrations of sertraline and N-desmethylsertraline was found in patients carrying slow allelic variants rs3892097, rs1065852, rs16947 of the CYP2D6 gene. A statistically significant moderate inverse correlation was found between the dose and the metabolic ratio C6-HO-THBC/CP. The results obtained are preliminary, which makes it necessary to continue the study with an expanded sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Biochemistry and Genetics, Ufa Federal Research Center, Russian Academy of Sciences, Ufa, 450054 Russia.
- Russian Medical Academy of Continuing Professional Education of the Ministry of Health of Russia, Moscow, 125993 Russia.
- annagareeva@yandex.ru.
- Moscow Scientific and Practical Center of Narcology of the Moscow City Health Department, Moscow, 109390 Russia.
- Republican Narcological Dispensary of the Ministry of Health of the Republic of Bashkortostan no. 1, Ufa, 450057 Russia.
- Scientific Center for Mental Health, Moscow, 115522 Russia.
Zitieren
APA
Gareeva, A. E., Nasibullin, T. R., Pozdnyakov, S. A., Borodina, L. S., Timerbulatov, I. F., Baymeeva, N. V., Bagaev, D. E., & Smirnov, V. V. (2025). Personalised Pharmacotherapy with Sertraline in Patients with Anxiety—Depressive Disorder Based on Omics Biomarkers. Молекулярная биология / Molecular Biology, 59(6), 928. https://doi.org/10.7868/s3034555325060041
Vancouver
Gareeva AE, Nasibullin TR, Pozdnyakov SA, Borodina LS, Timerbulatov IF, Baymeeva NV, et al. Personalised Pharmacotherapy with Sertraline in Patients with Anxiety—Depressive Disorder Based on Omics Biomarkers. Молекулярная биология / Molecular Biology. 2025;59(6):928. doi:10.7868/s3034555325060041
BibTeX
@article{Gareeva2025,
author = {Gareeva, A E and Nasibullin, T R and Pozdnyakov, S A and Borodina, L S and Timerbulatov, I F and Baymeeva, N V and Bagaev, D E and Smirnov, V V},
title = {Personalised Pharmacotherapy with Sertraline in Patients with Anxiety—Depressive Disorder Based on Omics Biomarkers},
journal = {Молекулярная биология / Molecular Biology},
year = {2025},
volume = {59},
number = {6},
pages = {928},
doi = {10.7868/s3034555325060041}
}
EUVIMED